5005 McConnell Avenue
Los Angeles, CA 90066
United States
310 665 2928
https://www.armatapharma.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 66
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Deborah L. Birx M.D. | CEO & Director | 500,36k | N/A | 1957 |
Mr. Richard Rychlik | VP, Corporate Controller & Principal Financial Officer | 282,02k | N/A | 1956 |
Dr. Mina Pastagia M.D., MS | Chief Medical Officer | 432,57k | N/A | 1975 |
Mr. Peter Hubbard | Vice President of Operations | N/A | N/A | N/A |
Dr. Pierre Kyme Ph.D. | Senior Vice President of Business & Corporate Development | N/A | N/A | N/A |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Armata Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.